nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0864	0.277	CbGbCtD
Carfilzomib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.077	0.247	CbGbCtD
Carfilzomib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0557	0.179	CbGbCtD
Carfilzomib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0383	0.123	CbGbCtD
Carfilzomib—ABCB1—Glyburide—type 2 diabetes mellitus	0.0285	0.0914	CbGbCtD
Carfilzomib—ABCB1—Losartan—type 2 diabetes mellitus	0.0261	0.0836	CbGbCtD
Carfilzomib—PSMB8—islet of Langerhans—type 2 diabetes mellitus	0.00562	0.0525	CbGeAlD
Carfilzomib—PSMB10—adipose tissue—type 2 diabetes mellitus	0.00557	0.0519	CbGeAlD
Carfilzomib—PSMB5—islet of Langerhans—type 2 diabetes mellitus	0.00497	0.0464	CbGeAlD
Carfilzomib—PSMB1—islet of Langerhans—type 2 diabetes mellitus	0.00434	0.0405	CbGeAlD
Carfilzomib—PSMB2—islet of Langerhans—type 2 diabetes mellitus	0.00424	0.0395	CbGeAlD
Carfilzomib—PSMB5—nephron tubule—type 2 diabetes mellitus	0.004	0.0373	CbGeAlD
Carfilzomib—PSMB8—pancreas—type 2 diabetes mellitus	0.00395	0.0369	CbGeAlD
Carfilzomib—PSMB10—liver—type 2 diabetes mellitus	0.0039	0.0364	CbGeAlD
Carfilzomib—PSMB8—cortex of kidney—type 2 diabetes mellitus	0.00388	0.0362	CbGeAlD
Carfilzomib—PSMB2—retina—type 2 diabetes mellitus	0.00362	0.0338	CbGeAlD
Carfilzomib—PSMB8—adipose tissue—type 2 diabetes mellitus	0.00359	0.0335	CbGeAlD
Carfilzomib—PSMB1—nephron tubule—type 2 diabetes mellitus	0.0035	0.0326	CbGeAlD
Carfilzomib—PSMB5—pancreas—type 2 diabetes mellitus	0.00349	0.0326	CbGeAlD
Carfilzomib—PSMB5—cortex of kidney—type 2 diabetes mellitus	0.00342	0.0319	CbGeAlD
Carfilzomib—PSMB2—nephron tubule—type 2 diabetes mellitus	0.00341	0.0318	CbGeAlD
Carfilzomib—PSMB5—adipose tissue—type 2 diabetes mellitus	0.00317	0.0296	CbGeAlD
Carfilzomib—PSMB1—cardiovascular system—type 2 diabetes mellitus	0.00314	0.0293	CbGeAlD
Carfilzomib—PSMB1—kidney—type 2 diabetes mellitus	0.00307	0.0287	CbGeAlD
Carfilzomib—PSMB2—cardiovascular system—type 2 diabetes mellitus	0.00306	0.0286	CbGeAlD
Carfilzomib—PSMB1—pancreas—type 2 diabetes mellitus	0.00305	0.0285	CbGeAlD
Carfilzomib—PSMB2—kidney—type 2 diabetes mellitus	0.003	0.028	CbGeAlD
Carfilzomib—PSMB1—cortex of kidney—type 2 diabetes mellitus	0.00299	0.0279	CbGeAlD
Carfilzomib—PSMB2—pancreas—type 2 diabetes mellitus	0.00298	0.0278	CbGeAlD
Carfilzomib—PSMB2—cortex of kidney—type 2 diabetes mellitus	0.00292	0.0272	CbGeAlD
Carfilzomib—PSMB1—adipose tissue—type 2 diabetes mellitus	0.00277	0.0258	CbGeAlD
Carfilzomib—PSMB2—adipose tissue—type 2 diabetes mellitus	0.0027	0.0252	CbGeAlD
Carfilzomib—PSMB8—liver—type 2 diabetes mellitus	0.00252	0.0235	CbGeAlD
Carfilzomib—PSMB5—liver—type 2 diabetes mellitus	0.00222	0.0207	CbGeAlD
Carfilzomib—PSMB1—liver—type 2 diabetes mellitus	0.00194	0.0181	CbGeAlD
Carfilzomib—PSMB2—liver—type 2 diabetes mellitus	0.00189	0.0177	CbGeAlD
Carfilzomib—Ritonavir—ABCC2—type 2 diabetes mellitus	0.00144	0.242	CrCbGaD
Carfilzomib—PSMB8—Glipizide—Tolazamide—type 2 diabetes mellitus	0.00144	0.173	CbGdCrCtD
Carfilzomib—PSMB8—Glipizide—Glimepiride—type 2 diabetes mellitus	0.00144	0.173	CbGdCrCtD
Carfilzomib—PSMB8—Glipizide—Tolbutamide—type 2 diabetes mellitus	0.00136	0.164	CbGdCrCtD
Carfilzomib—PSMB8—Glipizide—Gliclazide—type 2 diabetes mellitus	0.00136	0.164	CbGdCrCtD
Carfilzomib—PSMB8—Glipizide—Chlorpropamide—type 2 diabetes mellitus	0.00125	0.15	CbGdCrCtD
Carfilzomib—Lopinavir—CYP1A2—type 2 diabetes mellitus	0.00115	0.192	CrCbGaD
Carfilzomib—Ritonavir—CYP2E1—type 2 diabetes mellitus	0.00101	0.17	CrCbGaD
Carfilzomib—Ritonavir—CYP1A2—type 2 diabetes mellitus	0.000963	0.162	CrCbGaD
Carfilzomib—PSMB8—Glipizide—Glyburide—type 2 diabetes mellitus	0.000944	0.114	CbGdCrCtD
Carfilzomib—Lopinavir—CYP3A4—type 2 diabetes mellitus	0.000758	0.127	CrCbGaD
Carfilzomib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000647	0.00604	CbGeAlD
Carfilzomib—Ritonavir—CYP3A4—type 2 diabetes mellitus	0.000637	0.107	CrCbGaD
Carfilzomib—Neutropenia—Irbesartan—type 2 diabetes mellitus	0.000579	0.00222	CcSEcCtD
Carfilzomib—Nausea—Tolazamide—type 2 diabetes mellitus	0.000577	0.00222	CcSEcCtD
Carfilzomib—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000577	0.00222	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Irbesartan—type 2 diabetes mellitus	0.000575	0.00221	CcSEcCtD
Carfilzomib—Dyspnoea—Glipizide—type 2 diabetes mellitus	0.000575	0.00221	CcSEcCtD
Carfilzomib—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000574	0.00221	CcSEcCtD
Carfilzomib—Anorexia—Glimepiride—type 2 diabetes mellitus	0.000574	0.0022	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Metformin—type 2 diabetes mellitus	0.000573	0.0022	CcSEcCtD
Carfilzomib—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000573	0.0022	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Pioglitazone—type 2 diabetes mellitus	0.000563	0.00216	CcSEcCtD
Carfilzomib—Chills—Gliclazide—type 2 diabetes mellitus	0.000563	0.00216	CcSEcCtD
Carfilzomib—Anaemia—Glyburide—type 2 diabetes mellitus	0.000562	0.00216	CcSEcCtD
Carfilzomib—Oedema peripheral—Orlistat—type 2 diabetes mellitus	0.000561	0.00215	CcSEcCtD
Carfilzomib—Decreased appetite—Glipizide—type 2 diabetes mellitus	0.000561	0.00215	CcSEcCtD
Carfilzomib—Insomnia—Pioglitazone—type 2 diabetes mellitus	0.000559	0.00215	CcSEcCtD
Carfilzomib—Hyperglycaemia—Irbesartan—type 2 diabetes mellitus	0.000558	0.00214	CcSEcCtD
Carfilzomib—Pneumonia—Irbesartan—type 2 diabetes mellitus	0.000555	0.00213	CcSEcCtD
Carfilzomib—Nausea—Acarbose—type 2 diabetes mellitus	0.000555	0.00213	CcSEcCtD
Carfilzomib—ABCB1—retina—type 2 diabetes mellitus	0.000553	0.00516	CbGeAlD
Carfilzomib—Pain—Glipizide—type 2 diabetes mellitus	0.000551	0.00212	CcSEcCtD
Carfilzomib—Constipation—Glipizide—type 2 diabetes mellitus	0.000551	0.00212	CcSEcCtD
Carfilzomib—Dyspnoea—Pioglitazone—type 2 diabetes mellitus	0.000551	0.00212	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Sitagliptin—type 2 diabetes mellitus	0.000546	0.0021	CcSEcCtD
Carfilzomib—Leukopenia—Glyburide—type 2 diabetes mellitus	0.000544	0.00209	CcSEcCtD
Carfilzomib—Insomnia—Glimepiride—type 2 diabetes mellitus	0.000544	0.00209	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Irbesartan—type 2 diabetes mellitus	0.000544	0.00209	CcSEcCtD
Carfilzomib—Insomnia—Sitagliptin—type 2 diabetes mellitus	0.000543	0.00208	CcSEcCtD
Carfilzomib—Renal failure—Irbesartan—type 2 diabetes mellitus	0.000542	0.00208	CcSEcCtD
Carfilzomib—Blood creatinine increased—Ramipril—type 2 diabetes mellitus	0.000541	0.00208	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Losartan—type 2 diabetes mellitus	0.000541	0.00208	CcSEcCtD
Carfilzomib—Infection—Bromocriptine—type 2 diabetes mellitus	0.000539	0.00207	CcSEcCtD
Carfilzomib—Dyspnoea—Glimepiride—type 2 diabetes mellitus	0.000536	0.00206	CcSEcCtD
Carfilzomib—Nausea—Nateglinide—type 2 diabetes mellitus	0.000535	0.00205	CcSEcCtD
Carfilzomib—Cardiac disorder—Valsartan—type 2 diabetes mellitus	0.000535	0.00205	CcSEcCtD
Carfilzomib—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000533	0.00205	CcSEcCtD
Carfilzomib—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000533	0.00205	CcSEcCtD
Carfilzomib—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000528	0.00203	CcSEcCtD
Carfilzomib—Back pain—Gliclazide—type 2 diabetes mellitus	0.000528	0.00203	CcSEcCtD
Carfilzomib—Hyperglycaemia—Losartan—type 2 diabetes mellitus	0.000525	0.00202	CcSEcCtD
Carfilzomib—Decreased appetite—Glimepiride—type 2 diabetes mellitus	0.000523	0.00201	CcSEcCtD
Carfilzomib—Pneumonia—Losartan—type 2 diabetes mellitus	0.000522	0.00201	CcSEcCtD
Carfilzomib—Hypoaesthesia—Metformin—type 2 diabetes mellitus	0.000522	0.00201	CcSEcCtD
Carfilzomib—Decreased appetite—Sitagliptin—type 2 diabetes mellitus	0.000521	0.002	CcSEcCtD
Carfilzomib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000521	0.00486	CbGeAlD
Carfilzomib—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000519	0.00199	CcSEcCtD
Carfilzomib—Arthralgia—Glyburide—type 2 diabetes mellitus	0.000518	0.00199	CcSEcCtD
Carfilzomib—Anorexia—Bromocriptine—type 2 diabetes mellitus	0.000517	0.00199	CcSEcCtD
Carfilzomib—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000517	0.00199	CcSEcCtD
Carfilzomib—Oedema peripheral—Metformin—type 2 diabetes mellitus	0.000517	0.00199	CcSEcCtD
Carfilzomib—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000513	0.00197	CcSEcCtD
Carfilzomib—Pain—Sitagliptin—type 2 diabetes mellitus	0.000513	0.00197	CcSEcCtD
Carfilzomib—Renal failure—Losartan—type 2 diabetes mellitus	0.00051	0.00196	CcSEcCtD
Carfilzomib—PSMB8—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000509	0.0613	CbGdCrCtD
Carfilzomib—Neuropathy peripheral—Losartan—type 2 diabetes mellitus	0.000509	0.00195	CcSEcCtD
Carfilzomib—Anaemia—Gliclazide—type 2 diabetes mellitus	0.000505	0.00194	CcSEcCtD
Carfilzomib—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000504	0.00194	CcSEcCtD
Carfilzomib—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000496	0.0019	CcSEcCtD
Carfilzomib—Hypoaesthesia—Irbesartan—type 2 diabetes mellitus	0.000493	0.00189	CcSEcCtD
Carfilzomib—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000491	0.00189	CcSEcCtD
Carfilzomib—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000489	0.00188	CcSEcCtD
Carfilzomib—Headache—Repaglinide—type 2 diabetes mellitus	0.000488	0.00188	CcSEcCtD
Carfilzomib—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.000488	0.00187	CcSEcCtD
Carfilzomib—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000487	0.00187	CcSEcCtD
Carfilzomib—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000487	0.00187	CcSEcCtD
Carfilzomib—Thrombocytopenia—Glyburide—type 2 diabetes mellitus	0.000486	0.00187	CcSEcCtD
Carfilzomib—Back pain—Valsartan—type 2 diabetes mellitus	0.000485	0.00186	CcSEcCtD
Carfilzomib—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000484	0.00186	CcSEcCtD
Carfilzomib—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.000482	0.00185	CcSEcCtD
Carfilzomib—Back pain—Orlistat—type 2 diabetes mellitus	0.000479	0.00184	CcSEcCtD
Carfilzomib—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000477	0.00183	CcSEcCtD
Carfilzomib—Cough—Gliclazide—type 2 diabetes mellitus	0.000476	0.00183	CcSEcCtD
Carfilzomib—Anorexia—Glyburide—type 2 diabetes mellitus	0.000473	0.00182	CcSEcCtD
Carfilzomib—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000472	0.00181	CcSEcCtD
Carfilzomib—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000471	0.00181	CcSEcCtD
Carfilzomib—Chills—Metformin—type 2 diabetes mellitus	0.000471	0.00181	CcSEcCtD
Carfilzomib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000468	0.00437	CbGeAlD
Carfilzomib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000468	0.0018	CcSEcCtD
Carfilzomib—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000467	0.00179	CcSEcCtD
Carfilzomib—Arthralgia—Gliclazide—type 2 diabetes mellitus	0.000465	0.00179	CcSEcCtD
Carfilzomib—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000464	0.00178	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000464	0.00178	CcSEcCtD
Carfilzomib—Hypoaesthesia—Losartan—type 2 diabetes mellitus	0.000464	0.00178	CcSEcCtD
Carfilzomib—Nausea—Repaglinide—type 2 diabetes mellitus	0.000463	0.00178	CcSEcCtD
Carfilzomib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000463	0.00178	CcSEcCtD
Carfilzomib—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000461	0.00177	CcSEcCtD
Carfilzomib—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.00046	0.00177	CcSEcCtD
Carfilzomib—ABCB1—kidney—type 2 diabetes mellitus	0.000458	0.00427	CbGeAlD
Carfilzomib—ABCB1—pancreas—type 2 diabetes mellitus	0.000455	0.00425	CbGeAlD
Carfilzomib—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000452	0.00174	CcSEcCtD
Carfilzomib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000446	0.00416	CbGeAlD
Carfilzomib—Chills—Irbesartan—type 2 diabetes mellitus	0.000444	0.00171	CcSEcCtD
Carfilzomib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000443	0.0017	CcSEcCtD
Carfilzomib—Infection—Gliclazide—type 2 diabetes mellitus	0.000443	0.0017	CcSEcCtD
Carfilzomib—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000442	0.0017	CcSEcCtD
Carfilzomib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000441	0.00169	CcSEcCtD
Carfilzomib—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000439	0.00169	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000439	0.00169	CcSEcCtD
Carfilzomib—Cough—Valsartan—type 2 diabetes mellitus	0.000438	0.00168	CcSEcCtD
Carfilzomib—Renal failure—Ramipril—type 2 diabetes mellitus	0.000438	0.00168	CcSEcCtD
Carfilzomib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000438	0.00168	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Ramipril—type 2 diabetes mellitus	0.000436	0.00168	CcSEcCtD
Carfilzomib—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000436	0.00168	CcSEcCtD
Carfilzomib—Cough—Orlistat—type 2 diabetes mellitus	0.000433	0.00166	CcSEcCtD
Carfilzomib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000432	0.00166	CcSEcCtD
Carfilzomib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000431	0.00166	CcSEcCtD
Carfilzomib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00043	0.00165	CcSEcCtD
Carfilzomib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000429	0.00165	CcSEcCtD
Carfilzomib—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000427	0.00164	CcSEcCtD
Carfilzomib—Dizziness—Glipizide—type 2 diabetes mellitus	0.000426	0.00164	CcSEcCtD
Carfilzomib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000423	0.00162	CcSEcCtD
Carfilzomib—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000414	0.00159	CcSEcCtD
Carfilzomib—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000413	0.00385	CbGeAlD
Carfilzomib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000412	0.00158	CcSEcCtD
Carfilzomib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00041	0.00158	CcSEcCtD
Carfilzomib—Vomiting—Glipizide—type 2 diabetes mellitus	0.00041	0.00157	CcSEcCtD
Carfilzomib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000408	0.00157	CcSEcCtD
Carfilzomib—Infection—Valsartan—type 2 diabetes mellitus	0.000407	0.00156	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000406	0.00156	CcSEcCtD
Carfilzomib—Headache—Glipizide—type 2 diabetes mellitus	0.000404	0.00155	CcSEcCtD
Carfilzomib—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000403	0.00155	CcSEcCtD
Carfilzomib—Infection—Orlistat—type 2 diabetes mellitus	0.000402	0.00154	CcSEcCtD
Carfilzomib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000401	0.00154	CcSEcCtD
Carfilzomib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000398	0.00153	CcSEcCtD
Carfilzomib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000398	0.00153	CcSEcCtD
Carfilzomib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000397	0.00153	CcSEcCtD
Carfilzomib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000397	0.00152	CcSEcCtD
Carfilzomib—Hypertension—Metformin—type 2 diabetes mellitus	0.000394	0.00151	CcSEcCtD
Carfilzomib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000394	0.00151	CcSEcCtD
Carfilzomib—Back pain—Losartan—type 2 diabetes mellitus	0.000392	0.00151	CcSEcCtD
Carfilzomib—Anorexia—Valsartan—type 2 diabetes mellitus	0.00039	0.0015	CcSEcCtD
Carfilzomib—Muscle spasms—Losartan—type 2 diabetes mellitus	0.00039	0.0015	CcSEcCtD
Carfilzomib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000389	0.0015	CcSEcCtD
Carfilzomib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000387	0.00149	CcSEcCtD
Carfilzomib—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000386	0.00148	CcSEcCtD
Carfilzomib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000384	0.00148	CcSEcCtD
Carfilzomib—Nausea—Glipizide—type 2 diabetes mellitus	0.000383	0.00147	CcSEcCtD
Carfilzomib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000383	0.00147	CcSEcCtD
Carfilzomib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000381	0.00146	CcSEcCtD
Carfilzomib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000381	0.00146	CcSEcCtD
Carfilzomib—Pain—Gliclazide—type 2 diabetes mellitus	0.000381	0.00146	CcSEcCtD
Carfilzomib—Headache—Glimepiride—type 2 diabetes mellitus	0.000377	0.00145	CcSEcCtD
Carfilzomib—Cough—Irbesartan—type 2 diabetes mellitus	0.000376	0.00145	CcSEcCtD
Carfilzomib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000376	0.00144	CcSEcCtD
Carfilzomib—Anaemia—Losartan—type 2 diabetes mellitus	0.000375	0.00144	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000373	0.00143	CcSEcCtD
Carfilzomib—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000372	0.00143	CcSEcCtD
Carfilzomib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000371	0.00143	CcSEcCtD
Carfilzomib—Infection—Metformin—type 2 diabetes mellitus	0.00037	0.00142	CcSEcCtD
Carfilzomib—Insomnia—Valsartan—type 2 diabetes mellitus	0.00037	0.00142	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000369	0.00142	CcSEcCtD
Carfilzomib—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000367	0.00141	CcSEcCtD
Carfilzomib—Insomnia—Orlistat—type 2 diabetes mellitus	0.000366	0.00141	CcSEcCtD
Carfilzomib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000365	0.0014	CcSEcCtD
Carfilzomib—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000365	0.0014	CcSEcCtD
Carfilzomib—Leukopenia—Losartan—type 2 diabetes mellitus	0.000363	0.00139	CcSEcCtD
Carfilzomib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000359	0.00138	CcSEcCtD
Carfilzomib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000357	0.00137	CcSEcCtD
Carfilzomib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000356	0.00137	CcSEcCtD
Carfilzomib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000356	0.00137	CcSEcCtD
Carfilzomib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000356	0.00137	CcSEcCtD
Carfilzomib—Anorexia—Metformin—type 2 diabetes mellitus	0.000355	0.00137	CcSEcCtD
Carfilzomib—Cough—Losartan—type 2 diabetes mellitus	0.000354	0.00136	CcSEcCtD
Carfilzomib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000353	0.00136	CcSEcCtD
Carfilzomib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000352	0.00135	CcSEcCtD
Carfilzomib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000352	0.00135	CcSEcCtD
Carfilzomib—Constipation—Valsartan—type 2 diabetes mellitus	0.00035	0.00134	CcSEcCtD
Carfilzomib—Infection—Irbesartan—type 2 diabetes mellitus	0.00035	0.00134	CcSEcCtD
Carfilzomib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000349	0.00134	CcSEcCtD
Carfilzomib—Pain—Orlistat—type 2 diabetes mellitus	0.000346	0.00133	CcSEcCtD
Carfilzomib—Arthralgia—Losartan—type 2 diabetes mellitus	0.000345	0.00133	CcSEcCtD
Carfilzomib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000345	0.00133	CcSEcCtD
Carfilzomib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000344	0.00132	CcSEcCtD
Carfilzomib—Headache—Bromocriptine—type 2 diabetes mellitus	0.00034	0.00131	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.00034	0.0013	CcSEcCtD
Carfilzomib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00034	0.0013	CcSEcCtD
Carfilzomib—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000335	0.00129	CcSEcCtD
Carfilzomib—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000334	0.00128	CcSEcCtD
Carfilzomib—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000332	0.00128	CcSEcCtD
Carfilzomib—Infection—Losartan—type 2 diabetes mellitus	0.000329	0.00126	CcSEcCtD
Carfilzomib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000324	0.00125	CcSEcCtD
Carfilzomib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000324	0.00124	CcSEcCtD
Carfilzomib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000322	0.00124	CcSEcCtD
Carfilzomib—Fatigue—Metformin—type 2 diabetes mellitus	0.000321	0.00123	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000321	0.00123	CcSEcCtD
Carfilzomib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.00032	0.00123	CcSEcCtD
Carfilzomib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00032	0.00123	CcSEcCtD
Carfilzomib—Constipation—Metformin—type 2 diabetes mellitus	0.000319	0.00122	CcSEcCtD
Carfilzomib—Anorexia—Losartan—type 2 diabetes mellitus	0.000316	0.00121	CcSEcCtD
Carfilzomib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000316	0.00121	CcSEcCtD
Carfilzomib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000314	0.0012	CcSEcCtD
Carfilzomib—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000311	0.0012	CcSEcCtD
Carfilzomib—Headache—Glyburide—type 2 diabetes mellitus	0.000311	0.00119	CcSEcCtD
Carfilzomib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000306	0.00117	CcSEcCtD
Carfilzomib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000305	0.00117	CcSEcCtD
Carfilzomib—Cough—Ramipril—type 2 diabetes mellitus	0.000304	0.00117	CcSEcCtD
Carfilzomib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000303	0.00117	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000302	0.00116	CcSEcCtD
Carfilzomib—Pain—Irbesartan—type 2 diabetes mellitus	0.000301	0.00116	CcSEcCtD
Carfilzomib—Constipation—Irbesartan—type 2 diabetes mellitus	0.000301	0.00116	CcSEcCtD
Carfilzomib—Insomnia—Losartan—type 2 diabetes mellitus	0.000299	0.00115	CcSEcCtD
Carfilzomib—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000296	0.00114	CcSEcCtD
Carfilzomib—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000295	0.00113	CcSEcCtD
Carfilzomib—Nausea—Glyburide—type 2 diabetes mellitus	0.000295	0.00113	CcSEcCtD
Carfilzomib—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000295	0.00113	CcSEcCtD
Carfilzomib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000294	0.00113	CcSEcCtD
Carfilzomib—Asthenia—Orlistat—type 2 diabetes mellitus	0.00029	0.00111	CcSEcCtD
Carfilzomib—ABCB1—liver—type 2 diabetes mellitus	0.00029	0.0027	CbGeAlD
Carfilzomib—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000288	0.00111	CcSEcCtD
Carfilzomib—Fatigue—Losartan—type 2 diabetes mellitus	0.000285	0.0011	CcSEcCtD
Carfilzomib—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000283	0.00109	CcSEcCtD
Carfilzomib—Pain—Losartan—type 2 diabetes mellitus	0.000283	0.00109	CcSEcCtD
Carfilzomib—Constipation—Losartan—type 2 diabetes mellitus	0.000283	0.00109	CcSEcCtD
Carfilzomib—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00028	0.00108	CcSEcCtD
Carfilzomib—Headache—Gliclazide—type 2 diabetes mellitus	0.000279	0.00107	CcSEcCtD
Carfilzomib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000278	0.00107	CcSEcCtD
Carfilzomib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000278	0.00107	CcSEcCtD
Carfilzomib—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000277	0.00106	CcSEcCtD
Carfilzomib—Dizziness—Valsartan—type 2 diabetes mellitus	0.000271	0.00104	CcSEcCtD
Carfilzomib—Anorexia—Ramipril—type 2 diabetes mellitus	0.000271	0.00104	CcSEcCtD
Carfilzomib—Dizziness—Orlistat—type 2 diabetes mellitus	0.000268	0.00103	CcSEcCtD
Carfilzomib—Asthenia—Metformin—type 2 diabetes mellitus	0.000267	0.00103	CcSEcCtD
Carfilzomib—Nausea—Gliclazide—type 2 diabetes mellitus	0.000265	0.00102	CcSEcCtD
Carfilzomib—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000262	0.00101	CcSEcCtD
Carfilzomib—Vomiting—Valsartan—type 2 diabetes mellitus	0.00026	0.001	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000259	0.000994	CcSEcCtD
Carfilzomib—Vomiting—Orlistat—type 2 diabetes mellitus	0.000257	0.000988	CcSEcCtD
Carfilzomib—Insomnia—Ramipril—type 2 diabetes mellitus	0.000257	0.000986	CcSEcCtD
Carfilzomib—Headache—Valsartan—type 2 diabetes mellitus	0.000256	0.000985	CcSEcCtD
Carfilzomib—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000255	0.00098	CcSEcCtD
Carfilzomib—Headache—Orlistat—type 2 diabetes mellitus	0.000253	0.000973	CcSEcCtD
Carfilzomib—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000253	0.000972	CcSEcCtD
Carfilzomib—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000252	0.00097	CcSEcCtD
Carfilzomib—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000247	0.000948	CcSEcCtD
Carfilzomib—Dizziness—Metformin—type 2 diabetes mellitus	0.000247	0.000947	CcSEcCtD
Carfilzomib—Fatigue—Ramipril—type 2 diabetes mellitus	0.000245	0.00094	CcSEcCtD
Carfilzomib—Nausea—Valsartan—type 2 diabetes mellitus	0.000243	0.000934	CcSEcCtD
Carfilzomib—Constipation—Ramipril—type 2 diabetes mellitus	0.000243	0.000933	CcSEcCtD
Carfilzomib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000241	0.000925	CcSEcCtD
Carfilzomib—Nausea—Orlistat—type 2 diabetes mellitus	0.00024	0.000923	CcSEcCtD
Carfilzomib—Asthenia—Losartan—type 2 diabetes mellitus	0.000238	0.000913	CcSEcCtD
Carfilzomib—Vomiting—Metformin—type 2 diabetes mellitus	0.000237	0.000911	CcSEcCtD
Carfilzomib—Headache—Metformin—type 2 diabetes mellitus	0.000234	0.000897	CcSEcCtD
Carfilzomib—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000233	0.000894	CcSEcCtD
Carfilzomib—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000227	0.00087	CcSEcCtD
Carfilzomib—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000224	0.000862	CcSEcCtD
Carfilzomib—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000224	0.000859	CcSEcCtD
Carfilzomib—Nausea—Metformin—type 2 diabetes mellitus	0.000221	0.000851	CcSEcCtD
Carfilzomib—Headache—Irbesartan—type 2 diabetes mellitus	0.00022	0.000847	CcSEcCtD
Carfilzomib—Dizziness—Losartan—type 2 diabetes mellitus	0.000219	0.000841	CcSEcCtD
Carfilzomib—Vomiting—Losartan—type 2 diabetes mellitus	0.000211	0.000809	CcSEcCtD
Carfilzomib—Nausea—Irbesartan—type 2 diabetes mellitus	0.000209	0.000803	CcSEcCtD
Carfilzomib—Headache—Losartan—type 2 diabetes mellitus	0.000207	0.000797	CcSEcCtD
Carfilzomib—Asthenia—Ramipril—type 2 diabetes mellitus	0.000204	0.000782	CcSEcCtD
Carfilzomib—Nausea—Losartan—type 2 diabetes mellitus	0.000197	0.000755	CcSEcCtD
Carfilzomib—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000194	0.000746	CcSEcCtD
Carfilzomib—Dizziness—Ramipril—type 2 diabetes mellitus	0.000188	0.000721	CcSEcCtD
Carfilzomib—Vomiting—Ramipril—type 2 diabetes mellitus	0.000181	0.000693	CcSEcCtD
Carfilzomib—Headache—Ramipril—type 2 diabetes mellitus	0.000178	0.000683	CcSEcCtD
Carfilzomib—Nausea—Ramipril—type 2 diabetes mellitus	0.000169	0.000648	CcSEcCtD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	1.26e-05	4.11e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—type 2 diabetes mellitus	1.26e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—type 2 diabetes mellitus	1.26e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—type 2 diabetes mellitus	1.26e-05	4.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.25e-05	4.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	1.25e-05	4.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—type 2 diabetes mellitus	1.24e-05	4.04e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PCK1—type 2 diabetes mellitus	1.23e-05	4.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.21e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.21e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.21e-05	3.95e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	1.2e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—type 2 diabetes mellitus	1.2e-05	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ALB—type 2 diabetes mellitus	1.2e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ALB—type 2 diabetes mellitus	1.2e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ALB—type 2 diabetes mellitus	1.2e-05	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—type 2 diabetes mellitus	1.2e-05	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—RELA—type 2 diabetes mellitus	1.19e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.19e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—type 2 diabetes mellitus	1.19e-05	3.89e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—RELA—type 2 diabetes mellitus	1.19e-05	3.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ALB—type 2 diabetes mellitus	1.19e-05	3.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NFKB1—type 2 diabetes mellitus	1.18e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NFKB1—type 2 diabetes mellitus	1.18e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NFKB1—type 2 diabetes mellitus	1.18e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 2 diabetes mellitus	1.18e-05	3.85e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—type 2 diabetes mellitus	1.17e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—type 2 diabetes mellitus	1.17e-05	3.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NFKB1—type 2 diabetes mellitus	1.16e-05	3.8e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HK1—type 2 diabetes mellitus	1.15e-05	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—NOS3—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—NOS3—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—NOS3—type 2 diabetes mellitus	1.15e-05	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.15e-05	3.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.15e-05	3.74e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.15e-05	3.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—NOS3—type 2 diabetes mellitus	1.13e-05	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.13e-05	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.13e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.13e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.13e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.13e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	1.13e-05	3.68e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	1.12e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	1.11e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	1.11e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	1.11e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	1.11e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.11e-05	3.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—SRC—type 2 diabetes mellitus	1.1e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—SRC—type 2 diabetes mellitus	1.1e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—SRC—type 2 diabetes mellitus	1.1e-05	3.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—INS—type 2 diabetes mellitus	1.1e-05	3.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—INS—type 2 diabetes mellitus	1.1e-05	3.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—INS—type 2 diabetes mellitus	1.1e-05	3.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—SRC—type 2 diabetes mellitus	1.08e-05	3.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—INS—type 2 diabetes mellitus	1.08e-05	3.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.08e-05	3.52e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.08e-05	3.52e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.08e-05	3.52e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.08e-05	3.52e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-05	3.5e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	1.07e-05	3.48e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.06e-05	3.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.06e-05	3.46e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.05e-05	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—type 2 diabetes mellitus	1.05e-05	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—type 2 diabetes mellitus	1.05e-05	3.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.05e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.04e-05	3.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—type 2 diabetes mellitus	1.04e-05	3.38e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.02e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.02e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SRC—type 2 diabetes mellitus	1.02e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SRC—type 2 diabetes mellitus	1.02e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SRC—type 2 diabetes mellitus	1.02e-05	3.32e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-05	3.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.01e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.01e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.01e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.01e-05	3.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1e-05	3.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SRC—type 2 diabetes mellitus	1e-05	3.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	9.93e-06	3.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	9.91e-06	3.23e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—type 2 diabetes mellitus	9.78e-06	3.19e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—type 2 diabetes mellitus	9.73e-06	3.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—type 2 diabetes mellitus	9.64e-06	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—type 2 diabetes mellitus	9.64e-06	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—type 2 diabetes mellitus	9.64e-06	3.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.62e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	9.53e-06	3.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—type 2 diabetes mellitus	9.51e-06	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.48e-06	3.09e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.48e-06	3.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—type 2 diabetes mellitus	9.39e-06	3.06e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—type 2 diabetes mellitus	9.34e-06	3.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	9.25e-06	3.02e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.14e-06	2.98e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.1e-06	2.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—type 2 diabetes mellitus	9.08e-06	2.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—type 2 diabetes mellitus	9.08e-06	2.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—type 2 diabetes mellitus	9.08e-06	2.96e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	9.06e-06	2.96e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	9.06e-06	2.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RELA—type 2 diabetes mellitus	9.05e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RELA—type 2 diabetes mellitus	9.05e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RELA—type 2 diabetes mellitus	9.05e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—type 2 diabetes mellitus	9.03e-06	2.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—type 2 diabetes mellitus	9.02e-06	2.94e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—type 2 diabetes mellitus	8.99e-06	2.93e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—type 2 diabetes mellitus	8.98e-06	2.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—type 2 diabetes mellitus	8.97e-06	2.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—type 2 diabetes mellitus	8.95e-06	2.92e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—type 2 diabetes mellitus	8.93e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RELA—type 2 diabetes mellitus	8.92e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—type 2 diabetes mellitus	8.9e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—type 2 diabetes mellitus	8.9e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—type 2 diabetes mellitus	8.9e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	8.88e-06	2.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	8.83e-06	2.88e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	8.83e-06	2.88e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	8.83e-06	2.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—type 2 diabetes mellitus	8.78e-06	2.87e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	8.77e-06	2.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	8.62e-06	2.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	8.52e-06	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.39e-06	2.74e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	8.36e-06	2.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.35e-06	2.73e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—type 2 diabetes mellitus	8.33e-06	2.72e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—type 2 diabetes mellitus	8.29e-06	2.71e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.23e-06	2.69e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.19e-06	2.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.16e-06	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.16e-06	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.16e-06	2.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.05e-06	2.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	7.92e-06	2.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	7.92e-06	2.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	7.92e-06	2.58e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	7.77e-06	2.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.72e-06	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.72e-06	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.72e-06	2.52e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	7.7e-06	2.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.63e-06	2.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.63e-06	2.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.63e-06	2.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.61e-06	2.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	7.55e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	7.54e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.53e-06	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—type 2 diabetes mellitus	7.41e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—type 2 diabetes mellitus	7.41e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—type 2 diabetes mellitus	7.41e-06	2.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—type 2 diabetes mellitus	7.31e-06	2.38e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	7.24e-06	2.36e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	7.16e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	7.16e-06	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—type 2 diabetes mellitus	7.11e-06	2.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—type 2 diabetes mellitus	7.11e-06	2.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.11e-06	2.32e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—type 2 diabetes mellitus	7.01e-06	2.29e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	6.98e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—type 2 diabetes mellitus	6.98e-06	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—type 2 diabetes mellitus	6.94e-06	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.93e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.93e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.93e-06	2.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	6.87e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	6.87e-06	2.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—type 2 diabetes mellitus	6.84e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.83e-06	2.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—type 2 diabetes mellitus	6.8e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—type 2 diabetes mellitus	6.8e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—type 2 diabetes mellitus	6.8e-06	2.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—type 2 diabetes mellitus	6.75e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—type 2 diabetes mellitus	6.74e-06	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—type 2 diabetes mellitus	6.7e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.36e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.36e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.36e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—type 2 diabetes mellitus	6.32e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—type 2 diabetes mellitus	6.31e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—type 2 diabetes mellitus	6.31e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—type 2 diabetes mellitus	6.31e-06	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—type 2 diabetes mellitus	6.29e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.27e-06	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.23e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.23e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.23e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—type 2 diabetes mellitus	6.22e-06	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.15e-06	2.01e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	5.92e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.92e-06	1.93e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	5.89e-06	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.83e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	5.81e-06	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.8e-06	1.89e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	5.64e-06	1.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	5.49e-06	1.79e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	5.39e-06	1.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—type 2 diabetes mellitus	5.29e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—type 2 diabetes mellitus	5.29e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—type 2 diabetes mellitus	5.29e-06	1.73e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	5.27e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	5.26e-06	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—type 2 diabetes mellitus	5.21e-06	1.7e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	5.12e-06	1.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	5.06e-06	1.65e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	4.85e-06	1.58e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—type 2 diabetes mellitus	4.79e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.79e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—type 2 diabetes mellitus	4.79e-06	1.56e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	4.76e-06	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—type 2 diabetes mellitus	4.72e-06	1.54e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	4.61e-06	1.5e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	4.53e-06	1.48e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	4.52e-06	1.47e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	4.46e-06	1.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.42e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.42e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.42e-06	1.44e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.36e-06	1.42e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	3.93e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	3.86e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	3.54e-06	1.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.38e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	3.38e-06	1.1e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	3.09e-06	1.01e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	1.56e-06	5.08e-06	CbGpPWpGaD
